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INTRODUCTION
Successful vaccination against the SARS- CoV-2 
virus is a decisive development in the inter-
national response to the pandemic. It also 
has substantial implications for how govern-
ments and international bodies deploy their 
resources, as major decisions will need to be 
made in a fast- moving and uncertain envi-
ronment. Current trends in vaccine devel-
opment have stimulated much commentary 
on how vaccines deemed to be the safest 
and most effective should be allocated, both 
at the global level (to ensure access for low- 
income countries)1 2 and within countries 
(to prioritise critical personnel and the most 
vulnerable population groups).3 We recog-
nise the importance of mass vaccination as a 
public health measure, and the crucial need 
to promote equity and solidarity across coun-
tries.4 5 We also recognise that prioritisation is 
required within countries so that resources are 
directed to best protect life, reduce inequities 
and increase public confidence. However, 
based on analysis of the COVID-19 response 
so far, we would argue that at least three addi-
tional forms of prioritisation are required: 
between vaccines; between vaccines and other 
elements of the pandemic response; and 
between COVID-19 and other areas of health 
provision. In each case, decision makers 
should concentrate as much on infrastruc-
ture and implementation as on principles of 
resource allocation.
SELECTING VACCINES: THE LONG TERM
As we have already seen, there is a tempta-
tion for governments to invest most of their 
available resources in the vaccines exhibiting 
the greatest promise of efficacy and safety. 
However, there are many alternative vaccines 
currently undergoing phase III clinical trials. 
If the objective is to reduce the global burden 
of COVID-19 in the long term and avoid 
deepening inequities in the process, both 
vaccine cost- effectiveness and equity must be 
considered.
Asssessing cost- effectiveness between 
vaccines is hampered by their independent 
development and evaluation to date. Head- 
to- head comparisons may be further compro-
mised by the need to account for variations 
in effectiveness and their ability to protect 
different subpopulations. Ultimately, imple-
mentation costs are likely to prove to be as, 
if not more, important than narrow cost- 
effectiveness profiles in determining which 
options are best suited in any given context. 
Cost analysis should therefore encompass 
logistical and distribution issues, which 
are likely to be significant drivers of afford-
ability and influenced by, for example, the 
requirement for vaccine storage at very low 
temperatures.6
Vaccine costs and cost- effectiveness should 
be considered in the wider context of equity 
of access and outcome, and fair allocation 
Summary box
 ► Development of vaccines is a major breakthrough in 
the fight against the SARS- CoV-2 virus.
 ► Much attention has been paid to how to prioritise 
between patient groups for vaccination and how to 
ensure equity, especially in low- income countries, 
but there are other important decisions that need to 
be made.
 ► These decisions include: (a) choosing between the 
various vaccines that will become available, (b) con-
tinuing to invest in other aspects of the COVID-19 
response and (c) balancing the COVID-19 response 
with the need to invest in other healthcare that has 
suffered during the pandemic.
 ► Although these decisions are inherently difficult, 
principles of good priority setting can be helpful; 
these principles include: evidence- based and trans-
parent decision- making, participation of stakehold-
ers and a focus on the implementation of decisions.
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of resources within and across populations.7 8 Though 
COVID-19 vaccines may initially be funded by donors, all 
countries will need long- term, mass COVID-19 vaccina-
tion strategies to ensure equitable and sustainable prac-
tices. Circumstances in which access is dependent on 
out- of- pocket contributions, or where available vaccines 
are perceived as unsafe and/or ineffective, will fuel ineq-
uity, antivaccine propaganda, and black and grey vaccine 
markets.9
PRIORITISING ACROSS THE COVID-19 RESPONSE
The experience of COVID-19 so far has been marked by 
variation in system responses and notable resource short-
ages for both public health and treatment measures.10 
The cost of investing in mass vaccination should therefore 
be weighed against the continued need for these other 
public health and treatment measures, as the vaccine will 
not immediately eradicate the virus. Embedding vaccina-
tion programmes in a well- resourced overall pandemic 
strategy and infrastructure will help with roll- out. Contact 
tracing, protective equipment, treatment and environ-
mental mitigation strategies such as indoor ventilation 
will all still be required, although in (hopefully) reducing 
orders of magnitude. These tools will continue to play a 
critical role in the pandemic response in contexts where 
vaccines are not available for whole populations at once, 
or vaccine effectiveness diminishes. Recent reports of 
virus mutations in mink in Denmark and other countries 
and its potential spread to humans highlight the impor-
tance of ongoing vigilance and public health investment 
across the COVID-19 response.11
PRIORITISING ACROSS HEALTHCARE PROGRAMMES
An accompanying feature of the pandemic has been 
the suspension of many areas of routine care, including 
vaccination for preventable diseases.12 13 The ramifica-
tions of this will have to be dealt with not only in the 
months ahead but for many years to come. Backlogs and 
capacity constraints will result in excess mortality attribut-
able to COVID-19—already modelled for several disease 
areas such as cancer14 15 and cardiovascular disease.16 17 
Catching up on backlogs will place additional, competing 
demands on the resources available. Investment in vacci-
nation will need to account for this ‘suspended care 
need’ and should be weighed against the immediate and 
longer term requirements for the delivery of routine 
health programmes.
In lower income countries (LICs), the consequences 
are especially stark, with lives lost due to a lack of routine 
urgent care through unemployment, restrictions on 
movement and healthcare, as well as a wider reluctance 
to attend healthcare facilities due to fears of contracting 
COVID-19. Furthermore, previous health emergencies, 
such as the most recent Ebola outbreak in West Africa, 
have shown a decline in funding for other essential 
programmes such as child and maternal health services.18 
The impact of further diverting scarce resources away 
from other areas of need will therefore need to be closely 
monitored and evaluated in order to understand the 
potential consequences of placing a higher value on one 
life saved from COVID-19 over one life saved from other 
conditions.
FOCUS ON IMPLEMENTATION
Our analysis of COVID-19 international pandemic 
responses highlights the critical importance of plan-
ning for effective implementation of any mass vaccina-
tion programme.19 If the global community is seriously 
committed to a fair and just international COVID-19 
vaccination strategy, the conversation must go beyond 
mitigating inequities in nations’ purchasing power and 
access to safe and effective vaccines. There are addi-
tional inequities across and within countries in terms of 
the resources available for mobilisation and infrastruc-
ture in place to support a mass vaccination campaign.20 
Meanwhile, the burden on agencies at the forefront of 
the COVID-19 response cannot be overstated. Vaccine 
roll- out, however welcome, is an additional strain not 
only in LICs but also increasingly in high- income coun-
tries.21 22 There is a need to support health systems to 
sustain routine services—this is more critical for weaker 
health systems seeking to prevent excessive avoidable 
mortality.20 Lastly, as countries plan to roll out COVID-19 
vaccination, it is important that effective strategies to 
deal with vaccine hesitancy are developed and imple-
mented.23 24
CONCLUSIONS
The fundamental tenets of good priority setting include: 
taking an explicit approach to decision- making; mean-
ingful stakeholder engagement; consideration of public 
values, ensuring mechanisms for appeals and revisions; 
and use of relevant evidence.25 26 Furthermore, for priority 
setting to be impactful, resource allocation should be 
aligned with set priorities.25 27 In the case of vaccina-
tion against COVID-19, such tenets will be crucial, as 
mismanaged priority setting would have disastrous conse-
quences for health, equity and trust in public health and 
policymakers. However, the challenges extend beyond 
choosing which patient groups to prioritise, and there is 
a risk that a narrow focus on such questions will distract 
from other choices that need to be made.
When selecting between vaccines for investment, 
governments should balance the requirement for 
urgency with the importance of ongoing evidence- 
informed decision- making, as more becomes known 
about vaccine characteristics, adverse effects, duration 
of immunity and extent of protection from transmission. 
In evaluating vaccine options, decision makers should 
go beyond narrow cost- effectiveness profiling to assess 
implementation costs, especially those that are likely 
to vary across vaccines. Taking a ‘real world’ approach 
to priority setting requires decision makers to accept 
uncertainty with respect to the unfolding context, and 
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conflicting ethical imperatives both in policy and wider 
society. There are no simple decision rules that can be 
transferred across contexts28 and consistency will best be 
served by the building of ‘case law’ as a means to inform, 
defend and refine decisions, and enable constant and 
careful monitoring and evaluation to ensure the greatest 
impact.29
In these conditions of uncertainty and occasional 
conflict, the design of vaccination programmes cannot 
be a purely technical task, and hence, there is a need for 
greater participation in decision- making than has been 
exercised so far with, for example, poor gender and racial 
representation on COVID-19 planning task forces.30 
Successful vaccination programmes will require buy- in 
from patient groups, local implementers and healthcare 
professionals (including the largely unpaid community 
health workers who will be relied on to support vaccina-
tion programmes in LICs), as well as major players from 
industry and global donors. Most crucially, investment 
in COVID-19 vaccination should not be pursued at the 
expense of ongoing public health prevention and other 
health needs.
Health equity as an over- riding aim of the global 
COVID-19 response requires that priority setting goes 
beyond decision- making for vaccines and takes a more 
holistic view that also considers the challenges associated 
with the long- term effects of vaccine selection, priority 
setting across COVID-19 response and healthcare 
programmes as well as implementation.
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